Cargando…
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
BACKGROUND AND OBJECTIVES: Mechanisms of visual impairment in aquaporin 4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG)–associated disorder (MOGAD) are incompletely understood. The respective impact of optic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691219/ https://www.ncbi.nlm.nih.gov/pubmed/37429715 http://dx.doi.org/10.1212/NXI.0000000000200141 |
_version_ | 1785152696144101376 |
---|---|
author | Remlinger, Jana Bagnoud, Maud Meli, Ivo Massy, Marine Hoepner, Robert Linington, Christopher Chan, Andrew Bennett, Jeffrey L. Enzmann, Volker Salmen, Anke |
author_facet | Remlinger, Jana Bagnoud, Maud Meli, Ivo Massy, Marine Hoepner, Robert Linington, Christopher Chan, Andrew Bennett, Jeffrey L. Enzmann, Volker Salmen, Anke |
author_sort | Remlinger, Jana |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Mechanisms of visual impairment in aquaporin 4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG)–associated disorder (MOGAD) are incompletely understood. The respective impact of optic nerve demyelination and primary and secondary retinal neurodegeneration are yet to be investigated in animal models. METHODS: Active MOG(35-55) experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6Jrj mice, and monoclonal MOG-IgG (8–18C5, murine), recombinant AQP4-IgG (rAb-53, human), or isotype-matched control IgG (Iso-IgG, human) was administered 10 days postimmunization. Mobility impairment was scored daily. Visual acuity by optomotor reflex and ganglion cell complex thickness (GCC, 3 innermost retinal layers) by optical coherence tomography (OCT) were longitudinally assessed. Histopathology of optic nerve and retina was investigated during presymptomatic, acute, and chronic disease phases for immune cells, demyelination, complement deposition, natural killer (NK) cell, AQP4, and astrocyte involvement, retinal ganglion cells (RGCs), and Müller cell activation. Groups were compared by nonparametric tests with a p value <0.05 indicating statistical significance. RESULTS: Visual acuity decreased from baseline to chronic phase in MOG-IgG (mean ± standard error of the mean: 0.54 ± 0.01 to 0.46 ± 0.02 cycles/degree, p < 0.05) and AQP4-IgG EAE (0.54 ± 0.01 to 0.43 ± 0.02, cycles/degree, p < 0.05). Immune cell infiltration of optic nerves started in presymptomatic AQP4-IgG, but not in MOG-IgG EAE (5.85 ± 2.26 vs 0.13 ± 0.10 macrophages/region of interest [ROI] and 1.88 ± 0.63 vs 0.15 ± 0.06 T cells/ROI, both p < 0.05). Few NK cells, no complement deposition, and stable glial fibrillary acid protein and AQP4 fluorescence intensity characterized all EAE optic nerves. Lower GCC thickness (Spearman correlation coefficient r = −0.44, p < 0.05) and RGC counts (r = −0.47, p < 0.05) correlated with higher mobility impairment. RGCs decreased from presymptomatic to chronic disease phase in MOG-IgG (1,705 ± 51 vs 1,412 ± 45, p < 0.05) and AQP4-IgG EAE (1,758 ± 14 vs 1,526 ± 48, p < 0.01). Müller cell activation was not observed in either model. DISCUSSION: In a multimodal longitudinal characterization of visual outcome in animal models of MOGAD and NMOSD, differential retinal injury and optic nerve involvement were not conclusively clarified. Yet optic nerve inflammation was earlier in AQP4-IgG–associated pathophysiology. Retinal atrophy determined by GCC thickness (OCT) and RGC counts correlating with mobility impairment in the chronic phase of MOG-IgG and AQP4-IgG EAE may serve as a generalizable marker of neurodegeneration. |
format | Online Article Text |
id | pubmed-10691219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106912192023-12-02 Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations Remlinger, Jana Bagnoud, Maud Meli, Ivo Massy, Marine Hoepner, Robert Linington, Christopher Chan, Andrew Bennett, Jeffrey L. Enzmann, Volker Salmen, Anke Neurol Neuroimmunol Neuroinflamm Research Article BACKGROUND AND OBJECTIVES: Mechanisms of visual impairment in aquaporin 4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG)–associated disorder (MOGAD) are incompletely understood. The respective impact of optic nerve demyelination and primary and secondary retinal neurodegeneration are yet to be investigated in animal models. METHODS: Active MOG(35-55) experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6Jrj mice, and monoclonal MOG-IgG (8–18C5, murine), recombinant AQP4-IgG (rAb-53, human), or isotype-matched control IgG (Iso-IgG, human) was administered 10 days postimmunization. Mobility impairment was scored daily. Visual acuity by optomotor reflex and ganglion cell complex thickness (GCC, 3 innermost retinal layers) by optical coherence tomography (OCT) were longitudinally assessed. Histopathology of optic nerve and retina was investigated during presymptomatic, acute, and chronic disease phases for immune cells, demyelination, complement deposition, natural killer (NK) cell, AQP4, and astrocyte involvement, retinal ganglion cells (RGCs), and Müller cell activation. Groups were compared by nonparametric tests with a p value <0.05 indicating statistical significance. RESULTS: Visual acuity decreased from baseline to chronic phase in MOG-IgG (mean ± standard error of the mean: 0.54 ± 0.01 to 0.46 ± 0.02 cycles/degree, p < 0.05) and AQP4-IgG EAE (0.54 ± 0.01 to 0.43 ± 0.02, cycles/degree, p < 0.05). Immune cell infiltration of optic nerves started in presymptomatic AQP4-IgG, but not in MOG-IgG EAE (5.85 ± 2.26 vs 0.13 ± 0.10 macrophages/region of interest [ROI] and 1.88 ± 0.63 vs 0.15 ± 0.06 T cells/ROI, both p < 0.05). Few NK cells, no complement deposition, and stable glial fibrillary acid protein and AQP4 fluorescence intensity characterized all EAE optic nerves. Lower GCC thickness (Spearman correlation coefficient r = −0.44, p < 0.05) and RGC counts (r = −0.47, p < 0.05) correlated with higher mobility impairment. RGCs decreased from presymptomatic to chronic disease phase in MOG-IgG (1,705 ± 51 vs 1,412 ± 45, p < 0.05) and AQP4-IgG EAE (1,758 ± 14 vs 1,526 ± 48, p < 0.01). Müller cell activation was not observed in either model. DISCUSSION: In a multimodal longitudinal characterization of visual outcome in animal models of MOGAD and NMOSD, differential retinal injury and optic nerve involvement were not conclusively clarified. Yet optic nerve inflammation was earlier in AQP4-IgG–associated pathophysiology. Retinal atrophy determined by GCC thickness (OCT) and RGC counts correlating with mobility impairment in the chronic phase of MOG-IgG and AQP4-IgG EAE may serve as a generalizable marker of neurodegeneration. Lippincott Williams & Wilkins 2023-07-10 /pmc/articles/PMC10691219/ /pubmed/37429715 http://dx.doi.org/10.1212/NXI.0000000000200141 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Research Article Remlinger, Jana Bagnoud, Maud Meli, Ivo Massy, Marine Hoepner, Robert Linington, Christopher Chan, Andrew Bennett, Jeffrey L. Enzmann, Volker Salmen, Anke Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations |
title | Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations |
title_full | Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations |
title_fullStr | Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations |
title_full_unstemmed | Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations |
title_short | Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations |
title_sort | modeling mog antibody–associated disorder and neuromyelitis optica spectrum disorder in animal models: visual system manifestations |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691219/ https://www.ncbi.nlm.nih.gov/pubmed/37429715 http://dx.doi.org/10.1212/NXI.0000000000200141 |
work_keys_str_mv | AT remlingerjana modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT bagnoudmaud modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT meliivo modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT massymarine modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT hoepnerrobert modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT liningtonchristopher modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT chanandrew modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT bennettjeffreyl modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT enzmannvolker modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations AT salmenanke modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations |